On Tuesday, 15th of August, NDA Group and SSI Strategy announced the merger of their companies, creating an industry leading life sciences consulting firm.
This collaboration combines two trusted consultancies to provide end-to-end support for drug development companies, guiding them from concept to commercialization.
SSI Strategy brings exceptional medical, clinical, and development expertise to complement NDA’s regulatory capabilities. Their teams, comprising former Chief Medical Officers, Heads of Medical Affairs, Clinical Development, and Safety, along with seasoned business consultants, perfectly align with NDA’s network of 100+ ex-regulators and industry experts.
By leveraging their combined strengths, they can offer solutions covering the entire product lifecycle. From expediting clinical development strategies to navigating complex regulatory pathways and maximizing real-world evidence, they will help clients overcome obstacles and achieve their goals more efficiently.
For drug developers, this merger means access to a single partner that fulfills all your requirements. No more gaps – just tailored solutions that enhance the value of your assets from start to finish.
For NDA Group, this merger with SSI Strategy realizes their vision of becoming a comprehensive life sciences consultancy guiding product development from inception to launch.
Johan Strömquist, CEO of NDA Group, commented, “SSI’s unparalleled combination of business acumen and medical expertise has formed a unique space in the Life Sciences market. We are excited to join forces with them to expand upon this platform together. While NDA Group has been a world leading regulatory development consultancy for the past 25 years, there are still challenges that biotechs face that we have not been able to fully address. Together with SSI, we can not only optimize the regulatory path, but now also partner with our clients to execute the entire development program. For our clients, this will mean reduced risk, reduced costs, increased success rates and faster time to market. For the patient, this means higher quality treatments without unnecessary delay.”
The two companies eagerly anticipate collaborating as a united team and driving success together!